Related Experiment Video

Updated: Jun 12, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines

Anderson W Chuck1, Philip Jacobs, Gregory Tyrrell

  • 1Institute of Health Economics, Edmonton, Alberta, Canada. achuck@ihe.ca

Vaccine
|June 18, 2010
PubMed

Insights

The 13-valent pneumococcal conjugate vaccine (PCV-13) offers superior health and economic benefits compared to PCV-7 and PCV-10. Increased serotype coverage significantly reduces infectious disease burden through direct and herd immunity effects.

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics
  • Epidemiology

Background:

  • Three pneumococcal vaccines (PCV-7, PCV-10, PCV-13) exist for infants, targeting distinct serotypes.
  • Infant vaccination prevents pneumococcal disease directly and indirectly via herd immunity in unvaccinated populations.

Purpose of the Study:

  • To develop a comparative model assessing the health and economic consequences of PCV-7, PCV-10, and PCV-13.
  • To evaluate clinical and economic outcomes for vaccinated and unvaccinated individuals, considering herd effects.

Main Methods:

  • A population-level simulation model was developed for children under two years of age.
  • Vaccines evaluated included 7-valent (PCV-7), 10-valent (PCV-10), and 13-valent (PCV-13) formulations.
  • Outcomes were compared against a PCV-7 base case, incorporating direct and indirect (herd) effects.

Main Results:

  • PCV-13 demonstrated the greatest reduction in pneumococcal disease incidence, including hospitalized pneumonia, meningitis, and bacteremia.
  • PCV-13 also showed significant reductions in otitis media and overall pneumonia cases compared to PCV-7 and PCV-10.
  • PCV-13 was associated with the lowest healthcare service costs and the most substantial improvements in health outcomes.

Conclusions:

  • The 13-valent pneumococcal conjugate vaccine (PCV-13) offers significant public health and economic advantages.
  • Increased serotype coverage of PCV-13 is projected to substantially impact infectious diseases.
  • Both direct vaccination and indirect herd immunity effects contribute to PCV-13's overall benefit.
Abstract

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.